An advisory committee for the Food and Drug Administration (FDA) has narrowly voted to recommend the addition of six peptides to an approved list of ingredients for specialty pharmacies that compound custom medications. The Pharmacy Compounding Advisory Committee's decision, reached after a two-day hearing, could significantly alter how Americans access these compounds, leaning towards popular demand despite warnings from the agency's own scientists.
The peptides recommended for inclusion are BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. A seventh peptide, emideltide, was rejected due to particularly weak evidence for its proposed use in treating narcolepsy and opioid withdrawal, with clinical studies using a different administration route than proposed and lacking robust data.
The committee's votes highlighted a division between its members, many of whom run clinics that offer peptides, and FDA staff scientists who had unanimously opposed adding any peptides to the list. FDA staff cited concerns over a lack of substantial clinical trial data, potential inconsistencies in compounded batches, and the risk of adverse immune reactions.
Committee members who voted in favor argued that recommending these peptides could mitigate harm by steering consumers away from the unregulated online market, where such compounds are often sold as "research chemicals" without medical oversight or quality guarantees. Dr. Haleem Mohammed, a panel member, expressed concern that rejecting the peptides could push them further into the "gray market."
However, public health advocates and agency scientists voiced strong opposition, warning that adding these peptides could establish a concerning precedent. Dr. Adriane Fugh-Berman, a professor at Georgetown University, likened the situation to endorsing the manufacturing of heroin simply because a black market exists, arguing that increased demand should prompt further study rather than legalization.
Implications for Patients and Regulation
The committee's recommendation does not equate to FDA approval of the peptides as safe or effective, nor does it make them available as over-the-counter supplements. Instead, it opens a regulated pathway for licensed compounding pharmacies to legally obtain the raw ingredients and prepare them for individual patients with a doctor's prescription. While the process includes safeguards for ingredient sourcing and contamination testing, these custom-mixed products still bypass the rigorous safety tracking and labeling requirements associated with standard FDA-approved drugs.
Next Steps in the Approval Process
The committee's recommendations are non-binding. The FDA will review the meeting records, public comments, and votes before publishing proposed rules and opening them for further public feedback, a process that could take up to a year. However, officials like Health and Human Services Secretary Robert F. Kennedy Jr., who has publicly supported broader access to peptides, could potentially influence the timeline. The recommendations represent a significant development for the telehealth and wellness industries, which are positioned to benefit from expanded treatment options. Drug manufacturers, conversely, have opposed the move, viewing it as a potential loophole around established drug approval processes. Safety advocates and scientists remain concerned that the public may misinterpret the inclusion on this list as an official endorsement of safety and efficacy. The FDA's Russell Wesdyk noted during the hearing the difficulty in adding compounds to the list when their exact composition and origin remain unclear.